◎ Sugi Atlas

Atlas / Disease / Chikungunya

Chikungunya

disease
On this page

Also known as arbovirus A Chikungunya typeCHIKChikungunya feverChikungunya virus caused disease or disorderChikungunya virus disease or disorderChikungunya virus infectionChikungunya virus infectious diseaseCHIKV infectionCK

Summary

Chikungunya (MONDO:0017941) is a disease and 72 clinical trials. Top therapeutic interventions include sodium chloride and chikungunya virus, live attenuated. A subtype of Alphavirus infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
  • Phenotypes (HPO): 51
  • Clinical trials: 72

Clinical features

Epidemiology

Prevalence records

16 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Annual incidence1-9 / 1 000 0000.12EuropeValidated
Annual incidence<1 / 1 000 0000.02FranceValidated
Annual incidence1-9 / 1 000 0000.32BelgiumValidated
Annual incidence<1 / 1 000 0000.06FinlandValidated
Annual incidence1-9 / 1 000 0000.13GermanyValidated
Annual incidence1-9 / 1 000 0000.3ItalyValidated
Annual incidence<1 / 1 000 0000.02LatviaValidated
Annual incidence1-9 / 1 000 0000.35SpainValidated
Annual incidence1-9 / 1 000 0000.16SwedenValidated
Annual incidence1-9 / 1 000 0000.24United KingdomValidated
Annual incidence1-9 / 1 000 0000.4MaltaValidated
Annual incidence<1 / 1 000 0000.02SloveniaValidated
Annual incidence<1 / 1 000 000GreeceValidated
Annual incidence<1 / 1 000 000HungaryValidated
Annual incidence<1 / 1 000 000IrelandValidated
Annual incidence<1 / 1 000 000PortugalValidated

Signs & symptoms

Clinical features (HPO)

51 HPO clinical features (Orphanet curated; top 50 by frequency):

HPO IDTermFrequency
HP:0001945FeverVery frequent (80-99%)
HP:0002829ArthralgiaVery frequent (80-99%)
HP:0012378FatigueVery frequent (80-99%)
HP:0000745Diminished motivationFrequent (30-79%)
HP:0000988Skin rashFrequent (30-79%)
HP:0001369ArthritisFrequent (30-79%)
HP:0001386Joint swellingFrequent (30-79%)
HP:0001387Joint stiffnessFrequent (30-79%)
HP:0002315HeadacheFrequent (30-79%)
HP:0003326MyalgiaFrequent (30-79%)
HP:0005198Stiff interphalangeal jointsFrequent (30-79%)
HP:0007483Depigmentation/hyperpigmentation of skinFrequent (30-79%)
HP:0010741Pedal edemaFrequent (30-79%)
HP:0010783ErythemaFrequent (30-79%)
HP:0012733MaculeFrequent (30-79%)
HP:0030834Shoulder painFrequent (30-79%)
HP:0030839Knee painFrequent (30-79%)
HP:0040186Maculopapular exanthemaFrequent (30-79%)
HP:0000225Gingival bleedingOccasional (5-29%)
HP:0000282Facial edemaOccasional (5-29%)
HP:0000421EpistaxisOccasional (5-29%)
HP:0000613PhotophobiaOccasional (5-29%)
HP:0000716DepressionOccasional (5-29%)
HP:0000967PetechiaeOccasional (5-29%)
HP:0000989PruritusOccasional (5-29%)
HP:0000992Cutaneous photosensitivityOccasional (5-29%)
HP:0001892Abnormal bleedingOccasional (5-29%)
HP:0002013VomitingOccasional (5-29%)
HP:0002014DiarrheaOccasional (5-29%)
HP:0007473Crusting erythematous dermatitisOccasional (5-29%)
HP:0008066Abnormal blistering of the skinOccasional (5-29%)
HP:0009830Peripheral neuropathyOccasional (5-29%)
HP:0012219Erythema nodosumOccasional (5-29%)
HP:0025143ChillsOccasional (5-29%)
HP:0025232BursitisOccasional (5-29%)
HP:0025289Cervical lymphadenopathyOccasional (5-29%)
HP:0025337Red eyeOccasional (5-29%)
HP:0032063Ankle joint effusionOccasional (5-29%)
HP:0040165PeriostitisOccasional (5-29%)
HP:0100686EnthesitisOccasional (5-29%)
HP:0100769SynovitisOccasional (5-29%)
HP:0200037Skin vesicleOccasional (5-29%)
HP:0001250SeizureVery rare (<1-4%)
HP:0002383Infectious encephalitisVery rare (<1-4%)
HP:0002716LymphadenopathyVery rare (<1-4%)
HP:0002797OsteolysisVery rare (<1-4%)
HP:0003401ParesthesiaVery rare (<1-4%)
HP:0003406Peripheral nerve compressionVery rare (<1-4%)
HP:0012185Constrictive median neuropathyVery rare (<1-4%)
HP:0030880Raynaud phenomenonVery rare (<1-4%)

Identifiers

Disease identifiers

FieldValue
Canonical namechikungunya
Mondo IDMONDO:0017941
MeSHD065632
Orphanet324625
DOIDDOID:0050012
ICD-11900389391
NCITC128422
SNOMED CT111864006
UMLSC0008055
MedGen3362
GARD0006038
NORD924
Is cancer (heuristic)no

Also known as: arbovirus A Chikungunya type · CHIK · Chikungunya fever · Chikungunya virus caused disease or disorder · Chikungunya virus disease or disorder · Chikungunya virus infection · Chikungunya virus infectious disease · CHIKV infection · CK

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Togaviridae infectious disease › Alphavirus infectious disease › chikungunya

Related subtypes (5): O’nyong’nyong fever, Barmah forest virus disease, Ross river fever, Venezuelan equine encephalitis, western equine encephalitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugStatus
Chikungunya Virus, Live AttenuatedApproved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 72.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified43
PHASE38
PHASE28
PHASE18
EARLY_PHASE12
PHASE41
PHASE2/PHASE31
PHASE1/PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06928753PHASE4RECRUITINGReal-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion
NCT04838444PHASE3ACTIVE_NOT_RECRUITINGAntibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
NCT06007183PHASE3ACTIVE_NOT_RECRUITINGLong-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
NCT06973772PHASE3NOT_YET_RECRUITINGTrial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
NCT04546724PHASE3COMPLETEDPivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
NCT04566484PHASE2/PHASE3TERMINATEDSeamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia
NCT04650399PHASE3COMPLETEDA Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
NCT04786444PHASE3COMPLETEDStudy to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
NCT06028841PHASE3WITHDRAWNA Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
NCT07133178PHASE3WITHDRAWNA Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children
NCT02230163PHASE1/PHASE2UNKNOWNClinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins
NCT02562482PHASE2COMPLETEDTrial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
NCT02861586PHASE2COMPLETEDPhase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine
NCT03101111PHASE2COMPLETEDStudy of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area
NCT03483961PHASE2COMPLETEDTrial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
NCT03635086PHASE2COMPLETEDSafety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)
NCT03807843PHASE2COMPLETEDChikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
NCT03992872PHASE2COMPLETEDPhase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
NCT06106581PHASE2COMPLETEDA Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
NCT01489358PHASE1COMPLETEDChikungunya Virus Vaccine Trial in Healthy Adults
NCT03028441PHASE1COMPLETEDPhase I Trial of Measles Vectored Chikungungya Vaccine
NCT03382964PHASE1COMPLETEDStudy to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers
NCT03590392PHASE1COMPLETEDSafety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)
NCT04440774PHASE1COMPLETEDResearch Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.
NCT04441905PHASE1COMPLETEDPhase 1 Study of SAR440894 vs Placebo
NCT04603131PHASE1COMPLETEDClinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine
NCT06669208PHASE1COMPLETEDTrial of an Inactivated Chikungunya Virus Vaccine
NCT07394426EARLY_PHASE1NOT_YET_RECRUITINGA Phase I Study of PepGNP-ChikV in Healthy Volunteers
NCT03702348EARLY_PHASE1UNKNOWNResistance Exercise Program on the Functionality of Individuals With Chikungunya Fever
NCT04615364Not specifiedRECRUITINGGenetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
NCT04619823Not specifiedRECRUITINGVirological and Immunological Determinants of Arbovirus Infection in New Caledonia
NCT06859619Not specifiedNOT_YET_RECRUITINGSerological Measurement of Montpellier Professionals’ Contacts with Infectious Agents Responsible for Animal-borne Diseases
NCT06983548Not specifiedNOT_YET_RECRUITINGChikungunya Virus Detection in Semen
NCT07112846Not specifiedNOT_YET_RECRUITINGProspective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
NCT07120724Not specifiedRECRUITINGReal-World Study on Chinese Medicine for Treating Chikungunya Fever
NCT07126171Not specifiedNOT_YET_RECRUITINGA Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever
NCT07163845Not specifiedACTIVE_NOT_RECRUITINGAssessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
NCT07190560Not specifiedRECRUITINGAgainst Chikungunya Virus and Neonatal Infection
NCT07254702Not specifiedENROLLING_BY_INVITATIONProspective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
NCT07347002Not specifiedENROLLING_BY_INVITATIONObservational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
SODIUM CHLORIDE42
CHIKUNGUNYA VIRUS, LIVE ATTENUATED41

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 23

This page pulls from 23 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardoidefogardgenccgwasgwas_studyhgncicd11medgenmeshmimmondomondochildmondoparentncitnordorphanetsctidumls